Welcome to our dedicated page for ORASURE TECHNOLOGIES SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ORASURE TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ORASURE TECHNOLOGIES's regulatory disclosures and financial reporting.
OraSure Technologies President & CEO Carrie Eglinton-Manner bought 32,300 shares of common stock in an open-market transaction. The shares were purchased on March 20, 2026 at a weighted average price of $2.9287 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2025.
After this purchase, she directly owns 2,190,874 OraSure shares. The filing notes the shares were acquired through multiple trades within a price range of $2.86 to $2.98 per share.
OraSure Technologies senior vice president of finance and chief accounting officer Anthony Michele Marie reported routine equity compensation activity in common stock. On March 2, 2026, she received a grant of 42,982 shares of restricted stock that vest in three equal annual installments beginning on March 2, 2027, contingent on continued service.
On March 1, 2026, she acquired 14,183 shares in settlement of vested performance units, then had 4,062 shares and 10,817 shares withheld at $3.0425 per share to cover tax liabilities tied to vesting of performance units and restricted shares. After these transactions, she directly held 185,788 shares of OraSure common stock.
OraSure Technologies received an amended Schedule 13D from Altai Capital, led by Rishi Bajaj, reflecting an activist position. The reporting persons beneficially own 3,613,836 shares of common stock, representing 5.2% of the company based on 69,126,173 shares outstanding as of February 28, 2026.
On March 17, 2026, Altai Capital’s investment manager issued a press release with an open letter to the board outlining its case for change and reiterating its intention to solicit proxies to elect Rishi Bajaj and John Bertrand at the annual meeting. The full letter is filed as Exhibit 99.3.
Altai Capital, a shareholder owning approximately 5% of OraSure Technologies (OSUR), has filed a Schedule 14A nominating Rishi Bajaj and John Bertrand for the 2026 Annual Meeting and delivered a letter urging board change. Altai cites chronic underperformance (stock declines of 67% and 56% on 5- and 10-year bases as of 03/06/26), management compensation misalignment (an estimated $15 million earned by the CEO over her tenure), and capital allocation decisions including a $30 million investment in Sapphiros and a Sherlock Biosciences acquisition with contingent payments.
Altai requests a strategic review including consideration of a sale, seeks board seats for its nominees, and says it will solicit votes if no settlement is reached.
OraSure Technologies’ Chief Financial Officer Kenneth J. McGrath reported an open-market purchase of 22,021 shares of common stock. The shares were bought on March 13, 2026 at a weighted average price of $2.9985 per share, in multiple trades between $2.93 and $3.12. Following this transaction, he directly owns 557,262 shares. The purchase was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 28, 2025.
OraSure Technologies President & CEO Carrie Eglinton Manner purchased 22,022 shares of common stock in an open-market transaction at a weighted average price of $2.9985 per share.
The trade was executed under a pre-arranged Rule 10b5-1 trading plan, and following this purchase she directly owns 2,158,574 OraSure shares.
OraSure Technologies, Inc. details its diagnostics and sample management business in an annual report for the year ended December 31, 2025. The company develops rapid tests for HIV, hepatitis C, syphilis, Ebola, sickle cell and COVID-19, plus saliva, urine and microbiome collection systems sold globally to clinical, research and commercial customers.
In November 2025 OraSure acquired BioMedomics, adding the SickleSCAN rapid sickle cell test sold outside the U.S. The company is advancing new products, including a rapid molecular self-test for chlamydia and gonorrhea and an at-home Colli-Pee urine collection device for sexually transmitted infections, both with 510(k) submissions filed in December 2025 and under FDA review.
Revenue mix is shifting sharply as InteliSwab COVID-19 test sales fell from $257,493,000 in 2023 to $45,136,000 in 2024 and $620,000 in 2025, while OraQuick HIV revenue declined to $49,802,000 in 2025 and Genomics products to $31,546,000. A single non-commercial customer represented 63% of revenue in 2023, 24% in 2024 and about 3% in 2025, highlighting reduced concentration but significantly lower COVID-related volumes.
OraSure exited its substance abuse testing business, continues to invest in BARDA-supported Ebola and Marburg virus tests, and emphasizes intellectual property protection across its brands and collection technologies. As of December 31, 2025, the company employed 500 people and held an aggregate non‑affiliate market value of $218,472,693 as of June 30, 2025, with 69,126,173 common shares outstanding as of February 28, 2026.
OraSure Technologies, Inc. reported a change on its board of directors. On February 28, 2026, director David J. Shulkin, M.D. informed the board that he will resign as a director, including his role on the Compensation Committee, effective March 2, 2026.
The company stated that Dr. Shulkin’s decision to step down is not due to any dispute or disagreement with the board, the company, or its management. The board expressed its appreciation for his years of service and contributions. The filing was signed by President and Chief Executive Officer Carrie Eglinton Manner.
OraSure Technologies’ Chief Financial Officer Kenneth J. McGrath reported equity award activity in company stock. On March 1 and March 2, he acquired 88,348 and 26,814 shares of common stock at $0.00 per share through grants and settlement of vested performance units and restricted stock. On March 1, 7,639 and 20,745 shares were withheld at $3.0425 per share to cover tax liabilities tied to these vestings, rather than open-market sales. After these transactions, he directly owned 535,241 shares. The newly granted restricted stock is scheduled to vest in three equal annual installments beginning on March 2, 2027, conditioned on his continued service.
OraSure Technologies President & CEO Carrie Eglinton Manner reported equity compensation and related tax withholding transactions in company common stock. On March 2, 2026, she received a grant of 355,464 shares of restricted stock that vest in three equal annual installments beginning March 2, 2027, conditioned on continued service.
On March 1, 2026, she acquired 129,032 shares delivered in settlement of vested performance units and had 56,116 and 122,655 shares withheld at $3.0425 per share to cover tax liabilities tied to vesting of performance units and restricted shares. After these transactions, she directly owned 2,136,552 common shares.